The Journal of Urology
Volume 182, Issue 5 , Pages 2242-2249 , November 2009

Men Older Than 70 Years Have Higher Risk Prostate Cancer and Poorer Survival in the Early and Late Prostate Specific Antigen Eras

  • Leon Sun

      Affiliations

    • Nothing to disclose.
    • ,
  • Arthur A. Caire

      Affiliations

    • Nothing to disclose.
    • ,
  • Cary N. Robertson

      Affiliations

    • Financial interest and/or other relationship with EDAP-Technomed and Cytogen.
    • ,
  • Daniel J. George

      Affiliations

    • Financial interest and/or other relationship with Novartis Pharmaceuticals, Pfizer Inc., Astra Zeneca, Roche, Cougar, Wyeth, Genentech, Bayer, Sanofi-Aventis and Molecular Insight.
    • ,
  • Thomas J. Polascik

      Affiliations

    • Financial interest and/or other relationship with Galil.
    • ,
  • Kelly E. Maloney

      Affiliations

    • Nothing to disclose.
    • ,
  • Philip J. Walther

      Affiliations

    • Nothing to disclose.
    • ,
  • Danielle A. Stackhouse

      Affiliations

    • Nothing to disclose.
    • ,
  • Benjamin D. Lack

      Affiliations

    • Nothing to disclose.
    • ,
  • David M. Albala

      Affiliations

    • Financial interest and/or other relationship with Applied Medical, Sanofi-Aventis and GlaxoSmithKline.
    • ,
  • Judd W. Moul

      Affiliations

    • Corresponding Author InformationCorrespondence: Division of Urologic Surgery and Duke Prostate Center, Duke University Medical Center, PO Box 3707, Durham, North Carolina 27710 (telephone: 919-684-5057; FAX: 919-684-8794)
    • Financial interest and/or other relationship with Sanofi-Aventis, Astra Zeneca, GlaxoSmithKline, Novartis and Theralogix.

Received 12 March 2009

References 

  1. Dong F, Reuther AM, Magi-Galluzzi C, et al. Pathologic stage migration has slowed in the late PSA era. Urology. 2007;70:839
  2. Shikanov SA, Thong A, Gofrit ON, et al. Robotic laparoscopic radical prostatectomy for biopsy Gleason 8 to 10: prediction of favorable pathologic outcome with preoperative parameters. J Endourol. 2008;22:1477
  3. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149:185
  4. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320
  5. Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310
  6. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177:2106
  7. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. 2009;59:27
  8. Chun FK, Briganti A, Graefen M, et al. Development and external validation of an extended 10-core biopsy nomogram. Eur Urol. 2007;52:436
  9. Richstone L, Bianco FJ, Shah HH, et al. Radical prostatectomy in men aged >or=70 years: effect of age on upgrading, upstaging, and the accuracy of a preoperative nomogram. BJU Int. 2008;101:541
  10. Stephenson AJ, Scardino PT, Eastham JA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst. 2006;98:715
  11. Schroeck FR, Sun L, Freedland SJ, et al. Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis. 2008;11:371
  12. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71
  13. Loeb S, Hernandez DJ, Mangold LA, et al. Progression after radical prostatectomy for men in their thirties compared to older men. BJU Int. 2008;101:1503
  14. Froehner M, Koch R, Litz RJ, et al. Survival analysis in men undergoing radical prostatectomy at an age of 70 years or older. Urol Oncol. 2008;
  15. Karakiewicz PI, Benayoun S, Kattan MW, et al. Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J Urol. 2005;173:1930
  16. Kubricht WS, Kattan MW, Sartor O, et al. Race is not independently associated with a positive prostate biopsy in men suspected of having prostate cancer. Urology. 1999;53:553
  17. Rodriguez-Covarrubias F, Larre S, De LaTaille A, et al. The outcome of patients with pathological Gleason score >or=8 prostate cancer after radical prostatectomy. BJU Int. 2008;101:305
  18. Magheli A, Rais-Bahrami S, Humphreys EB, et al. Impact of patient age on biochemical recurrence rates following radical prostatectomy. J Urol. 2007;178:1933
  19. Labrie F, Candas B, Cusan L, et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate. 2004;59:311

 Study received institutional review board approval.

 Supported by research funds from the Committee for Urologic Research, Education, and Development (CURED) of Duke University.

 Editor's Note: This article is the second of 5 published in this issue for which category 1 CME credits can be earned. Instructions for obtaining credits are given with the questions on pages 2538 and 2539.

PII: S0022-5347(09)01763-7

doi: 10.1016/j.juro.2009.07.034

The Journal of Urology
Volume 182, Issue 5 , Pages 2242-2249 , November 2009

Article Tools

* Image Usage & Resolution